Browsing by Subject "AZELASTINE"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study
    (WILEY) Bousquet, J; Devillier, P; Arnavielhe, S; Bedbrook, A; Alexis-Alexandre, G; van Eerd, M; Murray, R; Canonica, GW; Illario, M; Menditto, E; Passalacqua, G; Stellato, C; Triggiani, M; Carreiro-Martins, P; Fonseca, J; Almeida, MM; Nogueira-Silva, L; Pereira, AM; Bom, AT; Bosse, I; Caimmi, D; Demoly, P; Fontaine, JF; Just, J; Onorato, GL; Kowalski, ML; Kuna, P; Samolinski, B; Anto, JM; Mullol, J; Valero, A; Tomazic, PV; Bergmann, KC; Keil, T; Klimek, L; Mösges, R; Shamai, S; Zuberbier, T; Murphy, E; McDowall, P; Price, D; Ryan, D; Sheikh, A; Chavannes, NH; Fokkens, WJ; Kvedariene, V; Valiulis, A; Bachert, C; Hellings, PW; Kull, I; Melen, E; Wickman, M; Bindslev-Jensen, C; Eller, E; Haahtela, T; Papadopoulos, NG; Annesi-Maesano, I; Bewick, M; Bosnic-Anticevich, S; Cruz, AA; De Vries, G; Gemicioglu, B; Larenas-Linnemann, D; Laune, D; Mathieu-Dupas, E; O'Hehir, RE; Pfaar, O; Portejoie, F; Siroux, V; Spranger, O; Valovirta, E; VandenPlas, O; Yorgancioglu, A
    BackgroundLarge observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect real-world everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology. MethodsA mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. ResultsA total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control). ConclusionsThis study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses.
  • No Thumbnail Available
    Item
    Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
    (MOSBY-ELSEVIER) Bédard, A; Basagaña, X; Anto, JM; Garcia-Aymerich, J; Devillier, P; Arnavielhe, S; Bedbrook, A; Onorato, GL; Czarlewski, W; Murray, R; Almeida, R; Fonseca, J; Costa, E; Malva, J; Morais-Almeida, M; Pereira, AM; Todo-Bom, A; Menditto, E; Stellato, C; Ventura, MT; Cruz, AA; Stelmach, R; da Silva, J; Larenas-Linnemann, D; Fuentes-Pérez, JM; Huerta-Villalobos, YR; Emuzyte, R; Kvedariene, V; Valiulis, A; Kuna, P; Samolinski, B; Klimek, L; Mösges, R; Pfaar, O; Shamai, S; Annesi-Maesano, I; Bosse, I; Demoly, P; Fontaine, JF; Cardona, V; Mullol, J; Valero, A; Roller-Wirnsberger, RE; Tomazic, PV; Chavannes, NH; Fokkens, WJ; Reitsma, S; Bewick, M; Ryan, D; Sheikh, A; Haahtela, T; Toppila-Salmi, S; Valovirta, E; Makris, M; Papadopoulos, NG; Prokopakis, EP; Psarros, F; Cingi, C; Gemicioglu, B; Yorgancioglu, A; Bosnic-Anticevich, S; O'Hehir, RE; Bachert, C; Hellings, PW; Pugin, B; Bindslev-Jensen, C; Eller, E; Kull, I; Melén, E; Wickman, M; De Vries, G; van Eerd, M; Agache, I; Ansotegui, IJ; Dykewicz, MS; Casale, T; Wallace, D; Waserman, S; Laune, D; Bousquet, J
    Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.